Fisetin is a naturally occurring flavonoid found at meaningful concentrations in strawberries, apples, persimmons, and onions. It has attracted research interest across several areas of aging biology, including its potential effects on bone metabolism. Bone is a living tissue in constant flux: specialized cells called osteoblasts build new matrix while osteoclasts dissolve old bone in a process called resorption. When resorption chronically outpaces formation, conditions such as osteoporosis can develop.
Some laboratory research has begun examining whether fisetin can influence osteoclast activity and, by extension, the balance of bone remodeling. This article summarizes what preclinical data currently show, explains the proposed cellular mechanisms in plain language, and is transparent about the significant gap between early laboratory findings and any established benefit in people. Fisetin is sold as a dietary supplement and is not approved by the FDA to treat, prevent, or cure osteoporosis or any other disease.
Key Takeaways
- Fisetin, a flavonoid found in strawberries and other fruits, has shown osteoclast-inhibiting effects in preclinical research by repressing NF-κB and MKP-1 signaling pathways [1].
- All current bone-health evidence for fisetin comes from cell culture and animal models; no clinical trials have established that fisetin supplementation reduces bone loss or fracture risk in humans.
- NF-κB is a key transcription factor driving osteoclast formation, making it a rational target for compounds aimed at slowing bone resorption, but many compounds that inhibit NF-κB in the lab do not translate to clinical benefit.
- Fisetin is available as a dietary supplement but is not FDA-approved for any bone-health or osteoporosis indication; its bioavailability after oral ingestion may limit how much reaches bone tissue.
- Established strategies for bone health, including adequate calcium and vitamin D, weight-bearing exercise, and physician-directed medications where warranted, have far stronger evidence than any flavonoid supplement.
Bone Remodeling and Why Osteoclasts Matter
Healthy bone is maintained by the coordinated activity of two opposing cell types. Osteoblasts synthesize collagen-rich matrix and then mineralize it, building bone density. Osteoclasts, which derive from the same monocyte-macrophage lineage as immune cells, secrete acids and enzymes that dissolve mineralized matrix, clearing damaged or aged bone so it can be replaced. This cycle, called bone remodeling, is essential for skeletal strength and calcium homeostasis throughout life.
When osteoclast activity becomes excessive relative to osteoblast-driven formation, net bone loss occurs. This imbalance underlies postmenopausal and age-related osteoporosis, where declining estrogen and other age-related changes tip the remodeling balance toward resorption. Many approved osteoporosis therapies, including bisphosphonates and denosumab, work by targeting osteoclast survival or activity. Researchers investigating plant polyphenols are asking whether compounds like fisetin might modulate the same cellular pathways, at least in laboratory settings.
The NF-κB Pathway: A Central Regulator of Osteoclast Formation
Nuclear factor kappa B (NF-κB) is a family of transcription factors that regulate inflammation, immune responses, and cell survival. In bone biology, NF-κB signaling is particularly important because it is activated downstream of RANK ligand (RANKL), the key signal that drives osteoclast precursor cells to differentiate into mature, bone-resorbing osteoclasts. Without adequate NF-κB activation, osteoclast formation is substantially impaired.
Compounds that can dampen NF-κB signaling in osteoclast precursors have therefore attracted attention as potential modulators of bone resorption. Many dietary polyphenols show NF-κB-inhibitory activity in various cell types under laboratory conditions, and fisetin is among those that have been tested specifically in osteoclast-relevant contexts. Understanding this pathway helps explain why researchers chose it as a target when evaluating fisetin’s effects on bone.
Fisetin's Proposed Mechanism: Evidence from a 2013 Preclinical Study
A 2013 study published in PloS One investigated how fisetin affects osteoclast biology and found that the polyphenol protects bone by repressing both NF-κB-dependent and MKP-1-dependent signaling pathways in osteoclasts [1]. MKP-1, or mitogen-activated protein kinase phosphatase-1, is an enzyme that regulates the activity of MAP kinases, which are themselves involved in the cellular stress responses and survival signals that osteoclasts depend on.
By suppressing these two distinct signaling arms, fisetin appeared in this preclinical model to reduce osteoclast differentiation and activity [1]. The convergence on two pathways is noteworthy because it suggests fisetin is not simply blocking a single molecular switch but may be influencing a broader network of signals that osteoclasts rely on for maturation and function. That said, all findings from this line of research are preclinical, meaning they were conducted in cell cultures or animal models, not in human clinical trials.
The same study also examined bone-related outcomes in model systems and found results consistent with reduced bone resorption in the presence of fisetin, supporting the mechanistic findings at the cellular level [1]. These results provide a plausible biological rationale for further investigation but do not establish that supplementing with fisetin produces clinically meaningful bone protection in humans.
What Preclinical Models Can and Cannot Tell Us
Cell culture studies and animal models are essential early steps in understanding whether a compound might have therapeutic value, but they are not substitutes for human clinical trials. Compounds frequently show promising effects in laboratory settings and later fail to demonstrate efficacy or safety in humans. Reasons include differences in how compounds are absorbed and metabolized, the complexity of whole-body physiology compared to isolated cells, dosing challenges, and the multifactorial nature of diseases like osteoporosis.
For fisetin specifically, an additional consideration is bioavailability. Fisetin is rapidly metabolized after oral ingestion, and the concentrations that showed effects in cell studies [1] may be difficult to achieve in bone tissue through supplementation alone. Researchers studying fisetin as a senolytic agent for other applications have used high intermittent doses precisely because sustained tissue concentrations are hard to maintain, and this dosing strategy has not been validated for bone outcomes in people.
This does not mean the preclinical findings are unimportant. They identify plausible mechanisms, help prioritize compounds for further study, and inform how future clinical trials might be designed. But anyone reading about fisetin and bone health should hold these findings as hypothesis-generating rather than practice-changing.
Dietary Sources of Fisetin and Everyday Exposure
Strawberries contain the highest reported concentrations of fisetin among commonly consumed foods, at roughly 160 micrograms per gram of fresh weight, though amounts vary by variety and ripeness. Other sources include apples, persimmons, grapes, onions, and cucumbers in smaller quantities. Routine dietary exposure from whole foods is well below the doses used in most preclinical research.
Fisetin is also available as a standalone dietary supplement, typically in capsule form at doses ranging from 100 mg to 500 mg per serving. Supplement products are not regulated as strictly as pharmaceutical drugs in the United States; purity, potency, and actual fisetin content can vary between brands. Third-party testing certifications from organizations such as NSF or USP provide some assurance of label accuracy. Because high intermittent doses have not been established as safe or effective for any specific condition, including bone health, consulting a qualified healthcare provider before beginning supplementation is appropriate.
Context Within the Broader Landscape of Bone Health Research
Osteoporosis affects hundreds of millions of people globally and is a major cause of fracture-related disability. Established interventions include adequate calcium and vitamin D intake, weight-bearing exercise, fall prevention strategies, and, where indicated, pharmaceutical agents such as bisphosphonates, selective estrogen receptor modulators, or biologic therapies. These approaches have robust evidence from randomized controlled trials measuring fracture outcomes.
Fisetin’s potential role in this landscape is, at present, exploratory. The osteoclast-inhibiting mechanisms identified in preclinical work [1] place it in a biologically plausible category of interest, but it sits alongside many other polyphenols and plant compounds that have shown similar effects in early research without progressing to proven human therapies. Enthusiasm for any single compound should be balanced against the full picture of what is clinically validated for bone protection.
🛒 Where to Buy Fisetin
- Life Extension Bio-FisetinLab-tested / studied
capsules, 24 mg per capsule (enhanced-bioavailability liposomal blend) — One of the category’s flagship products; liposomal delivery is designed to improve oral absorption; the lower per-capsule dose requires stacking multiple capsules for research-level senolytic protocols - NOW Foods Fisetin
capsules, 100 mg per capsule — NSF-certified GMP facility; widely available at retail and online; reliable entry-level option for low-dose daily regimens - Double Wood Supplements Fisetin
capsules, 100 mg per capsule (60 count) — USA-manufactured and third-party tested; consistently strong Amazon ratings; popular choice in r/longevity for cost-effective daily use - Swanson Fisetin
capsules, 100 mg per capsule — Established supplement brand with broad distribution; budget-friendly for users wanting a recognizable name at a low cost per dose
As an Amazon Associate we earn from qualifying purchases. Shilajit quality varies widely — always choose a product with a published third-party heavy-metal test (COA) before buying.
A Note on the Evidence
All bone-health findings for fisetin are from preclinical models and have not been replicated in human clinical trials, so no conclusions about efficacy in people can be drawn. Individuals on blood thinners, CYP3A4-sensitive medications, or with chronic health conditions should consult a physician before using fisetin supplements, as interactions and safety at higher doses have not been fully characterized.
Frequently Asked Questions
What is fisetin and where does it come from?
Fisetin is a plant polyphenol in the flavonol subclass found at the highest concentrations in strawberries and also present in apples, persimmons, grapes, onions, and cucumbers. It has been studied for a range of biological activities in preclinical settings, including effects on cellular senescence, inflammation, and, more recently, bone metabolism. It is not a drug and is sold in the United States as a dietary supplement.
How does fisetin affect osteoclasts in laboratory studies?
In preclinical research, fisetin was found to protect bone by repressing NF-κB-dependent and MKP-1-dependent signaling pathways within osteoclasts [1]. These two pathways are involved in osteoclast differentiation and survival, so suppressing them reduced the formation and activity of bone-resorbing cells in the experimental models studied. These are cell-level and animal-model findings and have not been confirmed in human trials.
Has fisetin been tested in humans for bone health or osteoporosis?
As of current available evidence, there are no published human clinical trials evaluating fisetin specifically for bone density, fracture risk, or osteoporosis outcomes. The available bone-relevant data come from a preclinical study in cell and animal models [1]. Early human trials of fisetin exist in other contexts, such as frailty and COVID-19, but they do not address bone endpoints.
Can eating more strawberries improve bone health through fisetin?
There is no direct evidence that increasing dietary fisetin from strawberries improves bone density or reduces fracture risk in people. Strawberries do provide other nutrients, including vitamin C, which supports collagen synthesis relevant to bone matrix. While a diet rich in fruits and vegetables is broadly associated with better health outcomes, attributing specific skeletal benefits to fisetin content specifically is not supported by current evidence.
Is fisetin safe to take as a supplement?
Fisetin has a reasonable short-term safety profile in the small human studies conducted to date for other applications, but high intermittent doses used in senolytic protocols have not been established as safe for long-term use. Fisetin can inhibit certain cytochrome P450 enzymes, particularly CYP3A4, and may interact with medications metabolized by that pathway. People taking blood thinners, immunosuppressants, or other CYP3A4-sensitive drugs should consult a physician before using fisetin supplements.
Should someone with osteoporosis take fisetin instead of prescribed medications?
No. Fisetin should not replace physician-prescribed osteoporosis therapies, which have been validated in large clinical trials for reducing fracture risk. The preclinical mechanistic findings on osteoclast inhibition [1] are an early research signal, not evidence of clinical efficacy. Anyone with diagnosed osteoporosis or significant bone loss should work with their healthcare provider on an evidence-based treatment plan before adding any supplement.
References
- Léotoing L et al. The polyphenol fisetin protects bone by repressing NF-κB and MKP-1-dependent signaling pathways in osteoclasts. PloS one (2013). PMID 23861901
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
